Article
Recombinant Human Erythropoietin to Target Cognitive Dysfunction in Bipolar Disorder
3 Jul 2014
Abstract excerpt
OBJECTIVE: Available drug treatments for bipolar disorder fail to reverse patients' cognitive deficits. Erythropoietin has neurotrophic actions and aids neurocognitive function. The aim of the study was to investigate the potential of erythropoietin to treat cognitive dysfunction in bipolar disorder. METHOD: Patients with an ICD-10 diagnosis of bipolar disorder in remission were randomized, with stratification by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
